Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
AJ Cooper, LV Sequist, JJ Lin - Nature Reviews Clinical Oncology, 2022 - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
[HTML][HTML] Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
C Zhou, KJ Tang, BC Cho, B Liu… - … England Journal of …, 2023 - Mass Medical Soc
Background Amivantamab has been approved for the treatment of patients with advanced
non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 …
non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 …
Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I …
K Park, EB Haura, NB Leighl, P Mitchell… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …
(EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
GJ Riely, JW Neal, DR Camidge, AI Spira, Z Piotrowska… - Cancer discovery, 2021 - AACR
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …
[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
[HTML][HTML] ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with
point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The …
point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …